Preventing future CV risks in women – let’s concentrate on pregnancy related disorders

10th February 2025, A/Prof Chee L Khoo

Adverse Pregnancy Outcomes?

We perform cardiovascular (CV) risk assessments in our consulting rooms everyday. We assess lipid profiles, smoking history, family history and activity levels in our patients routinely and try to quantify the likelihood they may have a cardiovascular event. Over the years at GPVoice we have tried to expand beyond the traditional risk factors as more data come to hand.…

Testosterone replacement – is it cardio safe?

31st May 2024, A/Prof Chee L Khoo

Testosterone Replacement

It’s coming to almost 10 years now when suddenly, we were not able to prescribe testosterone replacement therapy (TRT) to men with hypogonadism or low testosterone levels under the PBS. This came on the back of a decision by the US FDA in March 2015 to restrict the prescription of TRT (1).…

Low birth weight and future cardiovascular risk – how are they connected?

13th April 2019, Dr Chee L Khoo

We know that overweight children have higher future risk of cardiovascular disease and diabetes.  Ironically, babies who are small at birth or during infancy also have increased rates of cardiovascular disease and diabetes as adults. It is thought that foetal undernutrition at different stages of gestation are somehow link to this increased risk, but the underlying mechanism is not fully understood.…

Psoriatic Arthropathy & Metabolic Syndrome – the role of the GP

30th September 2018, Dr Chee L Khoo

10-40% of patients with psoriasis have joint manifestations as part of a multi-system inflammatory disease (1). There is a strong association between psoriasis and elements of metabolic syndrome. Recent evidence suggests that patients with psoriasis have increased cardio-metabolic morbidity and mortality. Like other auto-immune collagen diseases, psoriatic arthropathy (PsA) often necessitate a referral to the specialists to manage the systemic and joint disease.…

Sulfonylureas – the bad guy again!

30th September 2018, Dr Chee L Khoo

Sulfonylurea (SU) is still one of the most commonly prescribed anti-diabetic agent for type 2 diabetes (T2D)1. These patients may have put on a few kilograms of weight over the years but then they are overweight anyway. Weight gain when one gets older is pretty much expected anyway. They may have a few cardiovascular events here and there but then patients with T2D are known to have a higher risk of CV events.…